Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect.
A lactic acid bacterial strain was isolated from human fecal specimen and identified as Enterococcus faecalis SL-5. The isolated strain showed antimicrobial activity against Gram-positive pathogens assayed, especially the highest activity against Propionibacterium acnes. The antimicrobial substance was purified and verified as a bacteriocin (named ESL5) of E. faecalis SL-5 by activity-staining using P. acnes as an indicator. N-terminal sequence of ESL5 was determined (MGAIAKLVAK) and sequence analysis revealed that it is almost identical to the some of enterocins including L50A/B of E. faecium L50 and MR10A/B of E. faecalis MRR 10-3. From the sequencing data of L50A/B structural genes, the nucleotide sequence showed 100% identity with that of the MR10A/B structural genes, implying that ESL5 is an equivalent of enterocin MR10. Meanwhile, we also tested the therapeutic effect of anti-P. acnes activity in patients with mild to moderate acne because of its pathogenic role to acne vulgaris. For this purpose, a concentrated powder of CBT SL-5 was prepared using cell-free culture supernatant (CFCS) of E. faecalis SL-5 and included in a lotion for application in the patients. The study showed that CBT SL-5 lotion significantly reduced the inflammatory lesions like pustules compared to the placebo lotion. Therefore our results indicate that the anti-P. acnes activity produced by E. faecalis SL-5 has potential role to the treatment of acne as an alternative to topical antibiotics.
Kang
Bong Seon
BS
Department of Dermatology, Kangnam St. Mary's Hospital, Seoul 137-040, Republic of Korea.
Seo
Jae-Gu
JG
Lee
Gwa-Su
GS
Kim
Jung-Hwa
JH
Kim
Sei Yeon
SY
Han
Ye Won
YW
Kang
Hoon
H
Kim
Hyung Ok
HO
Rhee
Ji Hwan
JH
Chung
Myung-Jun
MJ
Park
Young Min
YM
D000152:Acne Vulgaris / Q000188:drug therapy*; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000096:biosynthesis* / Q000302:isolation & purification; D001430:Bacteriocins / Q000008:administration & dosage* / Q000096:biosynthesis* / Q000302:isolation & purification; D001483:Base Sequence; D002648:Child; D004269:DNA, Bacterial / Q000032:analysis; D004311:Double-Blind Method; D013293:Enterococcus faecalis / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D005243:Feces / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010802:Phylogeny; D011425:Propionibacterium acnes / Q000187:drug effects*; D017422:Sequence Analysis, DNA
D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D004269:DNA, Bacterial; C540497:ESL5 protein, Enterococcus faecalis